Liguzinediol
Liguzinediol is a protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) inhibitor that enhances the activity of sarcoplasmic reticulum Ca2+-ATPase (SERCA2a). Liguzinediol reduces the dephosphorylation level of phospholamban and increases the phosphorylation levels of phospholamban at serine-16 and threonine-17 sites. Liguzinediol exerts positive inotropic effects in rat hearts both in vivo and in vitro, and reverses caffeine-induced decrease in myocardial contractility in isolated rat hearts. Liguzinediol can be used for the research of heart failure.
For research use only. We do not sell to patients.
- CAS No.: 909708-65-2
- Formula: C8H12N2O2
- Molecular Weight:168.20
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Calcium Channel Isoforms
More
Biological Activity
Liguzinediol (100 μM; 30 min) inhibits the activities of PP1 and PP2A in left ventricular tissue extracts of rats[1].
Liguzinediol (1-100 μM; 30 min) enhances the phosphorylation of PLB at Ser-16 and Thr-17 in isolated rat ventricular myocytes in a concentration-dependent manner in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley (male, 300-350 g)[1]
-
Dosage:20 mg/kg
-
Administration:i.v.; single dose
-
Result:Decreased end-systolic volume from 82 μL to 65 μL.
Increased end-systolic pressure from 115 mm Hg to 141 mm Hg.
Increased stroke volume from 116 μL to 136 μL.
Increased ejection fraction from 58.6% to 67.6%.
Increased cardiac output from 27066 μL/min to 31312 μL/min.
Increased peak rate of rise of left ventricular pressure from 7207 mm Hg/s to 10022 mm Hg/s.
Increased stroke work from 10395 mm Hg/μL to 14988 mm Hg/μL.
Increased slope of end-systolic pressure-volume relationship from 0.96 to 1.24.
Caused no significant changes in heart rate, end-diastolic volume, end-diastolic pressure, or slope of end-diastolic pressure-volume relationship.
Chemical Information
-
CAS No. 909708-65-2
-
Molecular Weight 168.20
-
Formula C8H12N2O2
-
SMILES
OCC1=NC(=C(N=C1C)CO)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Liguzinediol Related Classifications
HY-121864 Related Classifications
Powered by Bioz